With an eye on the FDA, Lex­i­con and Sanofi line up more pos­i­tive da­ta on di­a­betes drug

Lex­i­con Phar­ma­ceu­ti­cals $LXRX is beef­ing up the pos­i­tive da­ta it’s been ac­cu­mu­lat­ing for the SGLT1/SGLT2 in­hibitor so­tagliflozin as it preps ap­pli­ca­tions for Type 1 di­a­betes.

The in­Tan­dem2 study al­ready demon­strat­ed again that the drug sig­nif­i­cant­ly cut A1C in 24 weeks, and re­searchers can now point to fresh da­ta un­der­lin­ing how that ef­fect is sus­tained through the first full year of treat­ment. This study hit the pri­ma­ry and all sec­ondary end­points, in­clud­ing re­duced weight and blood pres­sure. And it’s three for three in Phase III.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.